Wei-Ting Chao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wei-Ting Chao has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Peng-Hui Wang
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
4 shared publications - Huann-Cheng Horng
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan
2 shared publications - Bor-Ching Sheu
Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Obstet & Gynecol, Taipei, Taiwan
1 shared publication Chang-Ching Yeh
Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; Institute of Clinical Medicine, National Yang-Ming University, Taipei 112, Taiwan, ROC; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan, ROC; Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
1 shared publicationChen-Hao Lin
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
1 shared publicationChen‐Hao Lin
Department of Obstetrics and Gynecology Taipei Veterans General Hospital Taipei Taiwan
1 shared publication
Latest Publications
- Open Access
- 4 May 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 175 (1) , 453-465
α2,3‐Sialyltransferase ( ST3Gal1 ) regulates endometrioid‐type epithelial ovarian cancer cell migration and invasion via VEGF ‐ R2 / JAK2 / STAT3 signaling cascades
Objective: To investigate the role of ST3 β‐galactoside α‐2,3‐sialyltransferase 1 (ST3Gal1) and vascular endothelial growth factor receptor 2 (VEGF‐R2) in endometrioid‐type epithelial ovarian cancer (E‐OC) because aberrant α2,3‐sialylation mediated by ST3Gal1 and VEGF‐R2‐related angiogenesis is linked with tumor progression. Methods: ST3Gal1 and VEGF‐R2 expression levels were analyzed in E‐OC tissues and cell lines. ST3Gal1 knockdown and ST3Gal1 inhibitor soyasaponin I (SsaI) treatment were performed to evaluate the effects of altered sialylation on the VEGF‐R2 pathway, downstream Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling, and cell migration/invasion. Co‐immunoprecipitation experiments were conducted to confirm the interaction between ST3Gal1 and VEGF‐R2. The combination of SsaI and VEGF‐R2 inhibitors was assessed using in vitro and in vivo studies. Results: High ST3Gal1 expression was associated with advanced E‐OC stage and poorer overall survival in a univariable analysis; however, it did not retain independent prognostic significance in a multivariable analysis. ST3Gal1 knockdown reduced VEGF‐R2 expression and inhibited downstream JAK2/STAT3 signaling and suppressed tumor cell migration and invasion. SsaI treatment reduced VEGF‐R2 signaling and impaired metastatic potential in vitro. The combined inhibition of ST3Gal1 and VEGF‐R2 reduced tumor growth in vivo. Conclusions: Targeting ST3Gal1‐mediated α2,3‐sialylation disrupts VEGF‐R2 signaling and suppresses metastatic behavior in E‐OC models. Although clinical associations suggest a potential link with adverse outcomes, larger studies are required to clarify its independent prognostic significance. Combined inhibition of ST3Gal1 and VEGF‐R2 reduced tumor growth in vivo; these findings support further investigations of ST3Gal1 as a potential therapeutic target in E‐OC.
- 4 May 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 175 (1) , 453-465
Open Accessα2,3‐Sialyltransferase ( ST3Gal1 ) regulates endometrioid‐type epithelial ovarian cancer cell migration and invasion via VEGF ‐ R2 / JAK2 / STAT3 signaling cascades
Objective: To investigate the role of ST3 β‐galactoside α‐2,3‐sialyltransferase 1 (ST3Gal1) and vascular endothelial growth factor receptor 2 (VEGF‐R2) in endometrioid‐type epithelial ovarian cancer (E‐OC) because aberrant α2,3‐sialylation mediated by ST3Gal1 and VEGF‐R2‐related angiogenesis is linked with tumor progression. Methods: ST3Gal1 and VEGF‐R2 expression levels were analyzed in E‐OC tissues and cell lines. ST3Gal1 knockdown and ST3Gal1 inhibitor soyasaponin I (SsaI) treatment were performed to evaluate the effects of altered sialylation on the VEGF‐R2 pathway, downstream Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling, and cell migration/invasion. Co‐immunoprecipitation experiments were conducted to confirm the interaction between ST3Gal1 and VEGF‐R2. The combination of SsaI and VEGF‐R2 inhibitors was assessed using in vitro and in vivo studies. Results: High ST3Gal1 expression was associated with advanced E‐OC stage and poorer overall survival in a univariable analysis; however, it did not retain independent prognostic significance in a multivariable analysis. ST3Gal1 knockdown reduced VEGF‐R2 expression and inhibited downstream JAK2/STAT3 signaling and suppressed tumor cell migration and invasion. SsaI treatment reduced VEGF‐R2 signaling and impaired metastatic potential in vitro. The combined inhibition of ST3Gal1 and VEGF‐R2 reduced tumor growth in vivo. Conclusions: Targeting ST3Gal1‐mediated α2,3‐sialylation disrupts VEGF‐R2 signaling and suppresses metastatic behavior in E‐OC models. Although clinical associations suggest a potential link with adverse outcomes, larger studies are required to clarify its independent prognostic significance. Combined inhibition of ST3Gal1 and VEGF‐R2 reduced tumor growth in vivo; these findings support further investigations of ST3Gal1 as a potential therapeutic target in E‐OC.
- Top Cited PapersOpen Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (4)
PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan
Chao WT, et al. J Gynecol Oncol. 2026 ;37:e75. https://doi.org/10.3802/jgo.2026.37.e75
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (4)
Top Cited PapersOpen AccessPARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan
Chao WT, et al. J Gynecol Oncol. 2026 ;37:e75. https://doi.org/10.3802/jgo.2026.37.e75
- Open Access
- 11 November 2025
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 89 (1) , 25-34
Programmed death-ligand 1 upregulation is associated with poor prognosis in patients with epithelial ovarian cancer
Background: The clinical significance of programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC), particularly its association with platinum resistance (PR) and prognosis, remains unclear. This study aimed to evaluate the relationship between PD-L1 expression and PR in EOC and investigate cisplatin-induced PD-L1 modulation using in vitro and in vivo models. Methods: We retrospectively analyzed 189 patients with EOC, treated between 2014 and 2020. Tumor PD-L1 expression was assessed by immunohistochemistry (IHC) using the combined positive score (CPS). Serum PD-L1 levels were measured using enzyme-linked immunosorbent assay (ELISA). Cisplatin-induced PD-L1 regulation was examined in paired platinum-sensitive (PS: A2780 and ES2) and PR (A2780R and ES2R) cell lines and xenograft models. Results: High tumor PD-L1 expression (CPS ≥10) was more frequent in PR (38.5%) than in PS patients (19.0%, p < 0.01), and was associated with higher recurrence rates ( p < 0.001) and shorter overall survival ( p < 0.001). Serum PD-L1 concentrations were significantly elevated in patients with endometrioid and clear cell histologies compared with those in the control group ( p < 0.05). In vitro, PD-L1 expression was upregulated in PR cell lines compared with parental PS cell lines and was further increased following cisplatin exposure in a dose- and time-dependent manner. Xenograft models confirmed that cisplatin induces PD-L1 upregulation in both tumor tissue and serum, with more pronounced effects observed in PR tumors. Conclusion: PD-L1 upregulation (CPS ≥10) is associated with PR, disease recurrence, and poor prognosis in EOC. Endometrioid and clear cell histologic subtypes demonstrated higher baseline PD-L1 expression in our cohort. Cisplatin-induced PD-L1 upregulation represents a tumor-intrinsic response, particularly in PR tumor cells, highlighting PD-L1 as a histology-specific marker of poor prognosis and a potential therapeutic target in platinum-resistant EOC.
- 11 November 2025
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 89 (1) , 25-34
Open AccessProgrammed death-ligand 1 upregulation is associated with poor prognosis in patients with epithelial ovarian cancer
Background: The clinical significance of programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC), particularly its association with platinum resistance (PR) and prognosis, remains unclear. This study aimed to evaluate the relationship between PD-L1 expression and PR in EOC and investigate cisplatin-induced PD-L1 modulation using in vitro and in vivo models. Methods: We retrospectively analyzed 189 patients with EOC, treated between 2014 and 2020. Tumor PD-L1 expression was assessed by immunohistochemistry (IHC) using the combined positive score (CPS). Serum PD-L1 levels were measured using enzyme-linked immunosorbent assay (ELISA). Cisplatin-induced PD-L1 regulation was examined in paired platinum-sensitive (PS: A2780 and ES2) and PR (A2780R and ES2R) cell lines and xenograft models. Results: High tumor PD-L1 expression (CPS ≥10) was more frequent in PR (38.5%) than in PS patients (19.0%, p < 0.01), and was associated with higher recurrence rates ( p < 0.001) and shorter overall survival ( p < 0.001). Serum PD-L1 concentrations were significantly elevated in patients with endometrioid and clear cell histologies compared with those in the control group ( p < 0.05). In vitro, PD-L1 expression was upregulated in PR cell lines compared with parental PS cell lines and was further increased following cisplatin exposure in a dose- and time-dependent manner. Xenograft models confirmed that cisplatin induces PD-L1 upregulation in both tumor tissue and serum, with more pronounced effects observed in PR tumors. Conclusion: PD-L1 upregulation (CPS ≥10) is associated with PR, disease recurrence, and poor prognosis in EOC. Endometrioid and clear cell histologic subtypes demonstrated higher baseline PD-L1 expression in our cohort. Cisplatin-induced PD-L1 upregulation represents a tumor-intrinsic response, particularly in PR tumor cells, highlighting PD-L1 as a histology-specific marker of poor prognosis and a potential therapeutic target in platinum-resistant EOC.
- Open Access
- 20 August 2024
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 124 (8) , 746-751
Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study
- 20 August 2024
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 124 (8) , 746-751
Open AccessEfficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study
- Open Access
- 2 August 2023
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 50 (8) , 163
Prevalence, Treatments and Risk Factors of Pelvic Organ Prolapse and Urinary Incontinence
- 2 August 2023
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 50 (8) , 163
Open AccessPrevalence, Treatments and Risk Factors of Pelvic Organ Prolapse and Urinary Incontinence
- Open Access
- 28 March 2022
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 61 (2) , 282-289
A theoretical analysis of prophylactic common iliac arterial occlusion for potential massive bleeding during cesarean delivery: Decision-making considerations — A 2-year retrospective study
- 28 March 2022
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 61 (2) , 282-289
Open AccessA theoretical analysis of prophylactic common iliac arterial occlusion for potential massive bleeding during cesarean delivery: Decision-making considerations — A 2-year retrospective study
- Open Access
- 1 January 2019
- Published by SAGE Publications in Cancer Control
- Vol. 26 (1)
Evaluation of a Simple and Safe Tumor Drilling Technique to Potentiate the Effect of Intraperitoneal Chemotherapy in the Treatment of Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancer: A Matched Retrospective Cohort Study
Frontline intraperitoneal chemotherapy (IPCT) in the treatment of epithelial ovarian cancer has been well established. However, the role of second-line IPCT is yet to be confirmed. With a view to implementing IPCT to treat recurrent disease, a prerequisite is to perform a cytoreductive procedure to minimize residual tumor size. However, the role of cytoreductive procedure is still in debate due to a higher chance of complications. A matched retrospective cohort study was conducted. From 2008 to 2015, we adopted a relatively simple and safe tumor drilling technique to maximize tumor exposure to second-line IPCT. Patients who received tumor drilling followed by second-line IPCT constituted the cohort group. Concurrently, patients who received standard second-line systemic chemotherapy were selected as the comparison group. After propensity score matching, 85 patients in each group entered into the final analysis. The median progression-free survival was 7.3 months (95% confidence interval [CI], 6.2-7.8) for the cohort group versus 4.1 months (95% CI, 4.0-4.3) for the comparison group (hazard ratio = 0.25 [95% CI, 0.17-0.36]; P < .001, by log-rank test). The median overall survival was 33.6 months (32.1-36.6) for the cohort group versus 25.9 months (20.5-26.9) for the comparison group (hazard ratio = 0.33 [95% CI, 0.23-0.48]; P < .001, by log-rank test). Toxicities in the cohort group were not different from those that were published in reports of IPCT for ovarian cancer. The most commonly observed toxicity was gastrointestinal origin (51.7%), and it may be attributed to the intraperitoneal pharmacokinetic clearance of cisplatin and taxol and we also discussed the mechanism of gastrointestinal toxicity. Tumor drilling followed by second-line IPCT may confer a survival advantage over standard second-line systemic chemotherapy in the treatment of recurrent ovarian cancer.
- 1 January 2019
- Published by SAGE Publications in Cancer Control
- Vol. 26 (1)
Open AccessEvaluation of a Simple and Safe Tumor Drilling Technique to Potentiate the Effect of Intraperitoneal Chemotherapy in the Treatment of Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancer: A Matched Retrospective Cohort Study
Frontline intraperitoneal chemotherapy (IPCT) in the treatment of epithelial ovarian cancer has been well established. However, the role of second-line IPCT is yet to be confirmed. With a view to implementing IPCT to treat recurrent disease, a prerequisite is to perform a cytoreductive procedure to minimize residual tumor size. However, the role of cytoreductive procedure is still in debate due to a higher chance of complications. A matched retrospective cohort study was conducted. From 2008 to 2015, we adopted a relatively simple and safe tumor drilling technique to maximize tumor exposure to second-line IPCT. Patients who received tumor drilling followed by second-line IPCT constituted the cohort group. Concurrently, patients who received standard second-line systemic chemotherapy were selected as the comparison group. After propensity score matching, 85 patients in each group entered into the final analysis. The median progression-free survival was 7.3 months (95% confidence interval [CI], 6.2-7.8) for the cohort group versus 4.1 months (95% CI, 4.0-4.3) for the comparison group (hazard ratio = 0.25 [95% CI, 0.17-0.36]; P < .001, by log-rank test). The median overall survival was 33.6 months (32.1-36.6) for the cohort group versus 25.9 months (20.5-26.9) for the comparison group (hazard ratio = 0.33 [95% CI, 0.23-0.48]; P < .001, by log-rank test). Toxicities in the cohort group were not different from those that were published in reports of IPCT for ovarian cancer. The most commonly observed toxicity was gastrointestinal origin (51.7%), and it may be attributed to the intraperitoneal pharmacokinetic clearance of cisplatin and taxol and we also discussed the mechanism of gastrointestinal toxicity. Tumor drilling followed by second-line IPCT may confer a survival advantage over standard second-line systemic chemotherapy in the treatment of recurrent ovarian cancer.